# Research Pulse — 2026-09-16 _Generated 2026-09-16 07:31 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 16일 (수요일) · Synthesizing(종합) Day** 9/16(종합) → 9/15(검증) → 9/14(정밀화) → 9/13(가동화) → 9/12(다양화) → 9/11(전이) → 9/10(재보정) → 9/9(집약). Validating(9/15)된 기술들이 **세领域의跨눈역 통합·종합(Synthesizing) 단계로 이전하며 기존 분절된 성과를 unified frameworks로 연결하는 날** — Sawtell et al.으로 macrocyclic peptide의 cysteine-to-N-terminal cyclisation으로 covalent peptide inhibitor 발견(bioRxiv 2026), Na X.-M. et al.으로 IS110 transposon의 sequence-structure dual-match logic으로 표적 인식 충실도 확인(bioRxiv 2026), Wang S. et al.으로 SPARKLE의 high-resolution spatial transcriptomics에서 RNA leakage 보정(bioRxiv 2026), Ambardekar et al.으로 CRISPR gene editing cardiovascular disease ACC 2026 Scientific Statement 발표 — hepatocyte targets via LNP, curative treatments imminent(JACC 2026), Cai et al.으로 AI preclinical drug discovery 2020-2026 literature review — multimodal AI, digital twins, closed-loop automation 향후 방향(Pharmaceuticals 2026), Rui Zhao et al.으로 DNA/RNA editing therapy current status, challenges, future prospects 종합(Molecular Biomedicine 2026)이 동시에 진행된다. Synthesizing은 Validating의 다음 단계다. 오늘 6개 전선은 분절된 기술들이 **跨눈역 통합 프레임워크로 종합되며 새로운 치료적용 영역과 비표준 방법론의 통합 가능성을 동시에 탐색하는 날**이다. *출처: [Sawtell Macrocyclic Covalent Peptide bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.04.749435v1), [Na IS110 Transposon bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.03.19.712850v2), [Wang SPARKLE Spatial Transcriptomics bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.08.12.744394v2), [Ambardekar CRISPR Cardiovascular ACC JACC 2026](https://consensus.app/papers/details/d2b3d0973ec05b0fa332e49d7a7e9a63/), [Cai AI Preclinical Drug Discovery Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Rui Zhao DNA RNA Editing Therapy Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/)* *#SynthesizingDay #Sawtell #BioRxiv #Macrocyclic #CovalentPeptide #Cysteine #Cyclisation #Inhibitor #Na #IS110 #Transposon #DualMatch #SequenceStructure #TargetRecognition #Wang #SPARKLE #SpatialTranscriptomics #RNALeakage #Correction #Ambardekar #ACC #JACC #Cardiovascular #CRISPR #GeneEditing #LNP #Hepatocyte #Cai #Pharmaceuticals #AIPreclinical #Multimodal #DigitalTwin #ClosedLoop #RuiZhao #MolecularMediine #DNAEditing #RNAEditing #Delivery #Genotoxicity #Immunogenicity #Synthesizing #CrossDomain #Integration #DailyReport* --- ### Post 2: CRISPR & Gene Editing — Macrocyclic Covalent Peptide + IS110 Transposon Dual-Match Logic과 Cardiovascular CRISPR Statement 🪄 **[CRISPR/Gene Editing] Sawtell et al.으로 macrocyclic peptide의 cysteine-to-N-terminal cyclisation으로 covalent inhibitor 발견(bioRxiv 2026) + Na X.-M. et al.으로 IS110 transposon의 sequence-structure dual-match logic으로 target recognition fidelity 확인(bioRxiv 2026) + Ambardekar et al.으로 CRISPR cardiovascular disease ACC 2026 Scientific Statement — hepatocyte targets via LNP, curative treatments imminent(JACC 2026) + Rui Zhao et al.으로 DNA/RNA editing therapy comprehensive review — delivery·genotoxicity·immunogenicity(Molecular Biomedicine 2026): CRISPR의 Synthesizing(종합) 동시 확인** CRISPR/유전자 편집 기술의**跨눈역 통합과 새로운 치료 영역 종합(Synthesizing)**이 출처에서 동시에 확인된다[1][2][3][4]. **Macrocyclic Covalent Peptide: Cysteine-to-N-Terminal Cyclisation으로 Covalent Inhibitor 발견[1]** E. Sawtell et al.(bioRxiv 2026)의 연구는 macrocyclic peptide의 cysteine-to-N-terminal cyclisation으로 covalent peptide inhibitor 발견 방법을 제시한다. **Macrocyclic peptides 매력**: challenging protein targets engagement + drug-like properties 유지 가능. **핵심 혁신 — Cysteine-to-N-terminal cyclisation**: 기존 macrocyclization과 다른 새로운 토폴로지 확장 접근. **Covalent binding 의의**: 높은亲和力 결합 + 선택적 표적화. **적용 가능성**: previously challenging targets에 covalent inhibitor 개발. **핵심 메시지**: macrocyclic topology 확장으로 covalent peptide inhibitor 발견 — CRISPR/drug discovery Synthesizing. **IS110 Transposon: Sequence-Structure Dual-Match Logic으로 Target Recognition Fidelity[2]** X.-M. Na et al.(bioRxiv 2026)의 연구는 IS110 transposon의 표적 인식 충실도( fidelity)를 분석한다. **IS110 bridge RNA**: target site recognition directing. **핵심 발견 — Dual-match logic**: RNA-DNA base pairing 외에도 추가 특이성 층(sequence-structure dual-match) 존재. **ISPpu10 분석**: IS110 family의 표적 인식 메커니즘 심화. **핵심**: IS110 transposon의 sequence-structure dual-match logic — CRISPR 외gene delivery/platform Synthesizing. **ACC CRISPR Cardiovascular Disease 2026 Scientific Statement: Curative Treatments Imminent[3]** A. Ambardekar et al.(JACC 2026)의 statement는 CRISPR gene editing therapy의 cardiovascular disease 적용을 종합한다. **심혈관 질환의 유전적 기반**: many cardiovascular diseases have a genetic basis — gene sequencing으로 높은 rates의 genetic testing 가능. **CRISPR-Cas9 접근**: precise, targeted genome editing 가능. **LNP delivery**: hepatocyte-expressed treatment targets에 promising approach. **Curative treatments imminent**: exponential progress — curative treatments for some cardiovascular diseases imminent. **적용 가능 영역**: monogenic diseases, knockdown of protein production, liver-expressed protein synthesis errors (hypercholesterolemia, amyloidosis variants). **비용·윤리적 과제**: high-cost, single-treatment cures의 societal and ethical implications. **핵심**: ACC CRISPR cardiovascular statement — CRISPR 치료 영역 확장 Synthesizing. **DNA/RNA Editing Therapy Comprehensive Review: Delivery·Genotoxicity·Immunogenicity[4]** Rui Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA/RNA editing therapy의 현주소와 향후 방향을 종합한다. **핵심 성과 1 — Gene editing technologies 범위**: CRISPR-derived + newly developed RNA editing tools. **핵심 성과 2 — 기술 발전**: editing precision, hierarchical control, reversibility 향상. **핵심 성과 3 — 적용 분야**: inherited disorders, cancer, infectious diseases, neurodegenerative diseases. **핵심 성과 4 — In vivo application 핵심 병목**: (i) delivery efficiency, (ii) tissue specificity, (iii) genotoxicity, (iv) immunogenicity. **핵심 성과 5 — Safety assessment 확대**: genotoxicity + genomic structural variations 추적 포함. **핵심 성과 6 — 향후 전망**: programmable delivery systems + permanent/reversible editing strategies 결합으로 hard-to-transfect tissues와 complex diseases 치료 가능성 확대. **핵심**: DNA/RNA editing therapy comprehensive review — delivery/genotoxicity/immunogenicity 핵심 병목 종합 — CRISPR Synthesizing. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Sheikh Kresladi**로 **FDA LAD-I gene therapy 승인**(Validating — 규제 인정里程碑)을, **Jong PE1→PE7**로 **prime editing 진화 종합**(Validating)을 제시했다면, 오늘은 **Sawtell bioRxiv**으로 **macrocyclic covalent peptide inhibitor 발견**(Synthesizing — 새로운 치료적용 영역), **Na bioRxiv**으로 **IS110 dual-match logic**(Synthesizing — 새로운 gene delivery 플랫폼 메커니즘), **Ambardekar ACC**으로 **cardiovascular disease CRISPR 치료 적용**(Synthesizing — 세번째 질환 영역 확장), **Rui Zhao review**으로 **DNA/RNA editing의 delivery·genotoxicity·immunogenicity 핵심 병목 종합**(Synthesizing)을 동시에 제시한다. Validating(9/15) → CRISPR Synthesizing(9/16). 실무 함의: 제약 개발팀에서 Sawtell et al.의 covalent peptide approach와 Ambardekar et al.의 cardiovascular CRISPR 전략을 종합하여 cross-modality therapeutic strategy를 수립해야 한다. *출처: [Sawtell Macrocyclic Covalent Peptide bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.04.749435v1), [Na IS110 Transposon bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.03.19.712850v2), [Ambardekar CRISPR Cardiovascular ACC JACC 2026](https://consensus.app/papers/details/d2b3d0973ec05b0fa332e49d7a7e9a63/), [Rui Zhao DNA RNA Editing Therapy Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/)* *#CRISPR #GeneEditing #Sawtell #BioRxiv #Macrocyclic #CovalentPeptide #Cysteine #Cyclisation #Inhibitor #Na #IS110 #Transposon #DualMatch #SequenceStructure #TargetRecognition #Fidelity #Ambardekar #ACC #JACC #Cardiovascular #Coronary #HeartFailure #LNP #Hepatocyte #Curative #Imminent #RuiZhao #MolecularMediine #DNAEditing #RNAEditing #Delivery #Genotoxicity #Immunogenicity #SynthesizingDay #CrossDomain #Integration #NewModalities #Peptide #Transposon #CardiovascularDisease #RareDisease #DailyReport* --- ### Post 3: AI 신약 — AI Preclinical Drug Discovery Multimodal·Digital Twin·Closed-Loop Automation과 Phase II 한계 종합 💊 **[AI 신약] Cai et al.으로 AI preclinical drug discovery 2020-2026 literature review — drug-target·structure·de novo·virtual screening·ADMET + multimodal AI·digital twins·closed-loop automation 향후 방향(Pharmaceuticals 2026) + Rui Zhao et al.으로 DNA/RNA editing therapy delivery·genotoxicity 종합(Molecular Biomedicine 2026) + Mao et al.으로 AI Phase I 80-90%(Hist. 52%) BUT Phase II ~40% 근본 원인 target hypothesis validity 미개선(Frontiers Pharmacology 2026): AI drug discovery Synthesizing(종합) 동시 확인** AI-Driven Drug Discovery의**跨눈역 통합과 향후 방향 종합(Synthesizing)**이 출처에서 동시에 확인된다[4][5][6]. **AI Preclinical Drug Discovery: 2020-2026 Literature Review + 향후 방향[5]** M. Cai et al.(Pharmaceuticals 2026)의 review는 AI preclinical drug discovery의 2020-2026년 문헌을 종합한다. **적용 분야 6가지**: (i) drug-target interaction prediction, (ii) structure prediction, (iii) de novo design, (iv) virtual screening, (v) drug repurposing, (vi) ADMET forecasting. **핵심 성과 1 — 기술적 진전**: deep learning, protein language models, generative models 적용 확대. **핵심 성과 2 — 향후 방향 3가지**: (i) **Multimodal AI**: multimodal data 통합 — molecular, cellular, clinical data 연결, (ii) **Digital twins**: process optimization을 위한 digital twin 개념 확대, (iii) **Closed-loop automation**: computational prediction과 experimental validation의 자동화된 순환. **과제**: data quality, model interpretability, patient heterogeneity, regulatory adaptation. **핵심 메시지**: AI preclinical drug discovery 6분야 종합 + multimodal AI/digital twins/closed-loop automation今后 방향 — AI drug discovery Synthesizing. **DNA/RNA Editing Therapy: Delivery·Genotoxicity·Immunogenicity 종합[4]** Rui Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA/RNA editing therapy의 현재 상태와今后 과제를 종합한다[4]. **핵심 병목 4가지**: (i) delivery efficiency, (ii) tissue specificity, (iii) genotoxicity, (iv) immunogenicity. **Safety assessment 확대**: genotoxicity + genomic structural variations 추적. **Programmable delivery systems**: programmable delivery + permanent/reversible editing combinations. **적용 확대 전망**: hard-to-transfect tissues와 complex diseases 치료 가능성. **핵심**: DNA/RNA editing therapy 핵심 병목 종합 — AI + gene therapy Synthesizing. **AI Drug Discovery Phase II 한계 종합: Target Validity 미개선[6]** Z. Mao et al.(Frontiers in Pharmacology 2026)의 review는 AI drug discovery의 algorithmic foundations에서 clinical translation까지 분석한다[6]. **Phase I 성공률 80-90%**: AI-native pipelines vs historical ~52% — molecular safety engineering과 ADMET prediction 진정한 우위. **Phase II 성공률 ~40%**: AI ≈ conventional ~37% — 통계적으로 유의미한 차이 없음. **근본 원인**: Target hypothesis validity — AI는 올바른 biological premise 선택 확률 미개선. **AI 추가 가치**: 단백질 구조 예측, lead 최적화, timeline 압축. **AI 미개선 영역**: 타겟 검증, 환자 계층화, animal-to-human translation. 핵심: Phase I 우위 있으나 Phase II 차이 없음 — target validity 미개선 — AI drug discovery Synthesizing 한계 확인. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Khairil**으로 **AI validation crisis 90% 임상 실패율**(Validating)을, **Mao Phase I/II 분기**로 **target validity 미개선**(Validating)을 제시했다면, 오늘은 **Cai Pharmaceuticals**으로 **AI preclinical 6분야 종합 + multimodal AI/digital twins/closed-loop automation今后 방향**(Synthesizing — 향후 통합 프레임워크)을(new angle), **Rui Zhao DNA/RNA editing review**로 **gene therapy delivery 병목과 AI drug discovery 통합**(Synthesizing — cross-domain connection)을(new angle), **Mao Phase II 한계**를 **Synthesizing 문맥에서 재종합**으로 재제시한다. Validating(9/15) → AI drug discovery Synthesizing(9/16). 실무 함의: AI drug discovery 협업팀에서 Cai et al.의 multimodal AI/digital twins roadmap을 참조하여 AI-pharma integrated strategy를 수립해야 한다. *출처: [Cai AI Preclinical Drug Discovery Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Rui Zhao DNA RNA Editing Therapy Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)* *#AI #DrugDiscovery #Cai #Pharmaceuticals #Preclinical #MultimodalAI #DigitalTwin #ClosedLoop #Automation #DrugTarget #Structure #DeNovo #VirtualScreening #ADMET #RuiZhao #MolecularMediine #DNAEditing #RNAEditing #Delivery #Genotoxicity #Immunogenicity #Mao #FrontiersPharmacology #PhaseI #PhaseII #TargetValidity #SynthesizingDay #Integration #CrossDomain #FutureDirections #Pipeline #Industrialization #BiomedicalAI #DailyReport* --- ### Post 4: 단백질 AI — AlphaFold 종합과 Protein Language Model 향후 방향 종합 🔬 **[단백질 AI] Yin et al.으로 AlphaFold/Molecular Biosciences review — deep learning·protein language models·RoseTTAFold·ESMFold·drug discovery·enzyme engineering applications(Nature Methods 2026) + Mahtha et al.으로 AlphaFold2/3 monomeric 88%, dimeric 77% vs ESMFold monomeric 76%, dimeric 41% 체계적 benchmark(NAR Genomics Bioinformatics 2026) + Feldman et al.으로 AlphaFold3 adversarial 35% confidence reliability 한계(Computational Structural Biotechnology 2026): 단백질 AI Synthesizing(종합) 동시 확인** 단백질 AI의**방법론 종합과 향후 방향 제시(Synthesizing)**가 출처에서 동시에 확인된다[7][8][9]. **AlphaFold 종합 Review: Deep Learning·Protein Language Models·Applications[7]** T. Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 AI-driven protein structure prediction의 biochemical foundations에서 practical applications까지 종합한다. **핵심 성과 1 — 모델 비교**: AlphaFold3, RoseTTAFold( end-to-end neural architectures + evolutionary information + geometric constraints), ESMFold(single-sequence, 속도·scalability 우위). **핵심 성과 2 — 적용 분야**: drug discovery, enzyme engineering, disease research. **핵심 성과 3 — 현재 과제**: protein dynamics, post-translational modifications, protein-ligand interactions 모델링. **핵심 성과 4 — 향후 방향**: protein language models의持续发展 + experimental-computational integration. **핵심**: AlphaFold/protein language models comprehensive review — 단백질 AI Synthesizing. **AlphaFold vs ESMFold Benchmark: Monomeric/Dimeric 정확도 체계적 비교[8]** S.K. Mahtha et al.(NAR Genomics and Bioinformatics 2026)의 연구는 AlphaFold2, AlphaFold3, ESMFold의 예측 정확도를 비교한다[8]. **Benchmark 방법**: PDB 2022-2024 homolog 제외 후 1,666 monomeric + 994 dimeric proteins 선정. **핵심 성과 1 — AlphaFold2/3 monomeric 88%**: monomeric proteins에서 88% 정확도. **핵심 성과 2 — AlphaFold2/3 dimeric 77%**: dimeric proteins에서 77% 정확도. **핵심 성과 3 — ESMFold monomeric 76%**: monomeric에서 76% 정확도. **핵심 성과 4 — ESMFold dimeric 41%**: dimeric proteins에서 41% 정확도 — 현저히 낮음. **ProModEv portal**: interactive benchmarking data access. **핵심**: ESMFold dimeric 41% 한계 원인 — monomeric 특화, protein-protein interaction 미모델링 — 단백질 AI Synthesizing. **AlphaFold3 Adversarial Mutations: 35% Confidence Reliability 한계[9]** J. Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial evaluation을 수행한다[9]. **핵심 성과 1 — 40% residues invariance**: 점변이나 결실에도 구조 불변. **핵심 성과 2 — 35% confidence reliability**: confidence metrics가 most accurate structure를 선택하는 비율. **핵심 성과 3 — Template-based pattern matching 시사**: biophysical reasoning보다 memorized templates 의존 가능성. **핵심**: AlphaFold confidence metric limits + template-based pattern matching 문제 — 단백질 AI Synthesizing 한계. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Yin review**를 **AlphaFold/protein language models 향후 방향**(Validating)으로 제시했다면, 오늘은 **Yin**을 **Synthesizing 문맥에서 protein language models의 cross-domain integration**(drug discovery + enzyme engineering + disease research)으로 재해석하고, **Mahtha benchmark**를 **ESMFold dimeric 41% 원인 분석**(Synthesizing)으로, **Feldman adversarial**을 **Synthesizing 한계 종합**으로 재제시한다. Validating(9/15) → 단백질 AI Synthesizing(9/16). 실무 함의: 단백질 설계팀에서 Yin et al.의 comprehensive review를 참조하여 protein language model application strategy를 수립해야 한다. *출처: [Yin AlphaFold Protein Structure Prediction Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Mahtha AlphaFold ESMFold Benchmark NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/), [Feldman AlphaFold3 Adversarial Computational Structural Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)* *#ProteinAI #Yin #FrontiersMolecularBiosciences #AlphaFold #RoseTTAFold #ESMFold #ProteinLanguageModels #DeepLearning #Benchmark #Monomeric #Dimeric #88Percent #77Percent #76Percent #41Percent #Mahtha #NARGGenomics #ProModEv #Feldman #ComputationalStructuralBiotechnology #Adversarial #35Percent #Confidence #Reliability #TemplateBased #PatternMatching #SynthesizingDay #ComprehensiveReview #Applications #DrugDiscovery #EnzymeEngineering #DiseaseResearch #FutureDirections #Integration #DailyReport* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — SPARKLE RNA Leakage Correction Methodology Consolidation 🬬 **[Single-Cell Multi-Omics] Wang S. et al.으로 SPARKLE의 high-resolution spatial transcriptomics에서 RNA leakage 보정 — Stereo-seq + Visium HD용 evidence-constrained correction(bioRxiv 2026) + DenAdel et al.으로 scFM 22.2M cells × 400 models × 6,400 experiments — dataset scaling plateau, data scaling laws 없음(Nature Methods 2026) + Hou et al.으로 unified scFM framework 13 FMs + 50+ datasets benchmark — classical PCA 경쟁력 유지(bioRxiv 2026): single-cell Synthesizing(종합) 동시 확인** Single-Cell Foundation Model의**방법론 보정과 데이터 스케일링 한계 종합(Synthesizing)**이 출처에서 동시에 확인된다[10][17][18]. **SPARKLE: High-Resolution Spatial Transcriptomics RNA Leakage Correction[10]** S. Wang et al.(bioRxiv 2026)의 연구는 high-resolution spatial transcriptomics의 RNA leakage 보정 방법을 제시한다. **문제의식**: Stereo-seq와 Visium HD 같은 high-resolution sequencing-based spatial transcriptomics는 dense capture units를 cell-resolved expression matrices로 집계. **핵심 문제 — RNA leakage**: 조직 처리와 permeabilization 과정에서 local RNA leakage 발생. **SPARKLE 접근법**: evidence-constrained correction. **적용 플랫폼**: Stereo-seq, Visium HD. **핵심 성과 1 — Local RNA leakage 보정**: high-resolution spatial data의 정확도 향상. **핵심 성과 2 — Evidence-constrained method**: 실험적 증거 기반 보정. **핵심**: SPARKLE로 high-resolution spatial transcriptomics RNA leakage 보정 — single-cell Synthesizing methodology. **scFM Dataset Scaling: Plateau + No Data Scaling Laws[17]** A. DenAdel et al.(Nature Methods 2026)의 연구는 scFM dataset scaling 효과를 분석한다[17]. **실험 규모**: 22.2M cells corpus, 400개 모델 pre-training, 6,400개 experiments. **핵심 성과 1 — Scaling plateau**: 현재 방법들이 일부 데이터만으로도 plateau. **핵심 성과 2 — No data scaling laws**: large language models과 달리 clear scaling laws 없음. **핵심 성과 3 — 균형 강조**: model capacity, dataset size, computational resources 균형 중요. **핵심**: scFM dataset scaling plateau — single-cell Synthesizing methodology. **Unified scFM Framework: 13 FMs + 50+ Datasets[18]** S. Hou et al.(bioRxiv 2026)의 연구는 unified computational framework로 13개 FMs를 benchmark한다[18]. **핵심 성과 1 — Classical PCA 경쟁력 유지**: classical PCA approach remains competitive or even preferable. **핵심 성과 2 — FMs 우위 상황**: pre-trained embeddings가 biologically meaningful structure capture + low-label/transfer-learning scenarios에서 우위. **핵심 성과 3 — Technical barriers 감소**: unified framework로 technical barriers 감소. **핵심**: unified framework 13 FMs benchmark — classical PCA competitive + FMs advantages in specific scenarios — single-cell Synthesizing Consolidating. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Wang SCMBench**으로 **FMs < DMs**(Validating)를, **DenAdel**으로 **scFM dataset scaling plateau**(Validating)를 제시했다면, 오늘은 **Wang bioRxiv SPARKLE**으로 **RNA leakage correction이라는 새로운 방법론적 보정**(Synthesizing — spatial methodology Consolidation)을(new angle), **DenAdel**을 **Synthesizing 문맥에서 no scaling laws의 implications**로, **Hou**을 **classical PCA + FMs hybrid approach Synthesizing**으로 재제시한다. Validating(9/15) → Single-Cell Synthesizing(9/16). 실무 함의: 단일세포 분석팀에서 Wang et al.의 SPARKLE methodology를 참조하여 spatial transcriptomics data quality improvement strategy를 수립해야 한다. *출처: [Wang SPARKLE RNA Leakage Correction bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.08.12.744394v2), [DenAdel scFM Dataset Scaling Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Hou Unified scFM Framework bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.01.747412v1)* *#SingleCell #SpatialTranscriptomics #Wang #SPARKLE #BioRxiv #RNALeakage #Correction #Stereo-seq #VisiumHD #EvidenceConstrained #DenAdel #NatureMethods #scFM #DatasetScaling #Plateau #NoScalingLaws #22MillionCells #400Models #6400Experiments #Hou #BioRxiv #UnifiedFramework #13FMs #50Datasets #PCA #Competitive #TransferLearning #SynthesizingDay #Methodology #QualityImprovement #Integration #Atlas #DailyReport* --- ### Post 6: FDA/규제 — Kresladi LAD-I 승인 6개월 Follow-up과 Gene Therapy 综合展望 🏛️ **[FDA/규제] Sheikh et al.으로 FDA Kresladi(marnetegra-gene autotemcel) 승인 6개월 follow-up — LAD-I 최초 gene therapy, 2026-03-26 승인 후 real-world evidence 수집(Annals Medicine Surgery 2026) + Oo et al.으로 FDA gene therapy 1998-2025 evolution + platform technology designation + AI/ML mechanistic/model-informed(J Clinical Pharmacology 2026) + Shahzad et al.으로 FDA 38개 CGTs 86.8% orphan + 92.1% expedited + 73.7% 단일 pivotal study + 17.9% postmarketing efficacy 재확인(Clinical Pharmacology Therapeutics 2026): FDA/규제 Synthesizing(종합) 동시 확인** FDA/규제의**승인 후 follow-up과 종합 전망(Synthesizing)**이 출처에서 동시에 확인된다[13][14][15]. **Kresladi LAD-I 승인 6개월 Follow-up: Real-World Evidence 수집[13]** M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 연구는 FDA Kresladi gene therapy 승인(2026-03-26) 후 6개월 follow-up을 분석한다[13]. **LAD-I 개요**: 희귀 상염색체 열성 면역결핍, 2세 이내 75% 사망률. **Kresladi**: 첫 LAD-I gene therapy, pediatric patients 대상. **적용 대상**: matched sibling donor가 없는 pediatric LAD-I 환자. **6개월 follow-up 중요성**: real-world evidence 수집 + long-term safety monitoring 체계화. **핵심 메시지**: Kresladi 승인 후 follow-up 체계화 — gene therapy Synthesizing regulatory framework. **FDA Gene Therapy 1998-2025: Platform Technology + AI/ML Mechanistic Framework[14]** C. Oo et al.(The Journal of Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의演化와 향후 방향을 분석한다[14]. **승인 역사**: slow start → recent acceleration. **FDA Platform Initiatives 3가지**: (i) Plausible mechanism framework, (ii) CMC flexibility initiative, (iii) Advanced manufacturing technologies program. **AI/ML 역할**: dose selection, safety evaluation, durability prediction에서 mechanistic/model-informed drug development. **핵심**: FDA gene therapy regulatory evolution + platform technology designation — FDA Synthesizing. **FDA 38개 CGTs 규제 현황: 73.7% 단일 Pivotal + Postmarketing Efficacy 17.9%[15]** M. Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)의 연구는 FDA 38개 CGT의 규제 분석을 제시한다[15]. **Orphan designation**: 86.8%. **Expedited pathway**: 92.1%. **단일 pivotal study**: 73.7%. **Surrogate endpoints solely**: 44.7%. **Postmarketing requirements**: 73.4% (52개 후속 연구). **Postmarketing primary efficacy endpoint**: 17.9%만 포함. **핵심**: FDA CGT 규제 현실 — expedited approval + postmarketing evidence dependence — FDA Synthesizing. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Sheikh Kresladi**로 **FDA 승인里程碑**(Validating)을, **Oo/Shahzad FDA**로 **CGT 규제 체계**(Validating)를 제시했다면, 오늘은 **Sheikh Kresladi 6개월 follow-up**으로 **real-world evidence 수집 체계**(Synthesizing — 승인 후 lifecycle management)를(new angle), **Oo/Shahzad**를 **Synthesizing 문맥에서 gene therapy의 종합적 regulatory outlook**로 재제시한다. Validating(9/15) → FDA Synthesizing(9/16). 실무 함의: 규제 기획팀에서 Sheikh et al.의 Kresladi follow-up 체계와 Oo et al.의 platform technology designation을 종합하여 gene therapy regulatory lifecycle strategy를 수립해야 한다. *출처: [Sheikh Kresladi LAD-I FDA Approval Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Gene Therapy Evolution J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)* *#FDA #Regulation #GeneTherapy #CGTs #Sheikh #Kresladi #LAD-I #FDAApproval #Pediatric #FollowUp #RealWorldEvidence #ITGB2 #Oo #JClinicalPharmacology #PlatformTechnology #AI #ML #Mechanistic #ModelInformed #Shahzad #ClinicalPharmacologyTherapeutics #OrphanDesignation #ExpeditedPathway #SingleStudy #SurrogateEndpoints #Postmarketing #17Point9Percent #SynthesizingDay #LifecycleManagement #RegulatoryFramework #里程碑 #DailyReport* --- ### Post 7: Spatial Transcriptomics/Cancer Atlas — Gastric Cancer LAR/TLS Clinical Translation과 Pan-Cancer Atlas 임상 적용 전망 🗺️ **[Spatial Transcriptomics/Cancer Atlas] Gao et al.으로 gastric cancer Lymphocyte Aggregated Region(LAR) + TLS spatial characterization — Group A/B immune activation 차이, PD1+CD27+CD8 + CD70+LAMP3+ DC proximity(Nature Communications 2026) + Li et al.으로 12개 암종 56 LCPs · 13 niches · Niche_4/11 prognosis + immunotherapy resistance 예측 모델(Nature Medicine 2026) + Zhang et al.으로 SCLC 75 patients · 600,000+ cells · PIHS-1 survival predictor · vascular-immune crosstalk(Cell Reports Medicine 2026): Spatial Transcriptomics Synthesizing(종합) 동시 확인** Spatial Transcriptomics/Cancer Atlas의**면역치료 표적화·전망(Synthesizing)**이 출처에서 동시에 확인된다[12][16][11]. **Gastric Cancer LAR: Lymphocyte Aggregated Region + TLS Clinical Translation[16]** S. Gao et al.(Nature Communications 2026)의 연구는 gastric cancer의 spatial microenvironment를 특성화한다[16]. **핵심 성과 1 — Lymphocyte Aggregated Region(LAR)**: lymphocyte aggregates + tertiary lymphoid structures(TLS) 포함. **핵심 성과 2 — T Cell Activation Association**: Within LAR에서 naive T cell abundance와 T cell activation-associated pathways 연관. **핵심 성과 3 — Group A/B 차이**: Group A — more activated lymphocytes + adjacent cancerous regions; Group B — more resting lymphocytes. **핵심 성과 4 — PD1+CD27+CD8 + CD70+LAMP3+ DC proximity**: Group A 인접 종양 영역에서 클러스터. **핵심 성과 5 — 임상 적용 전망**: LAR/TLS 기반 면역치료 표적화 전략 가능성. **핵심**: Gastric cancer LAR + TLS spatial characterization + clinical translation outlook — spatial Synthesizing Consolidating. **Pan-Cancer Spatial Microenvironment: Niche_4/11 Immunotherapy Resistance Prediction[12]** J. Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종의 spatial transcriptomics를 수행한다[12]. **56 LCPs + 13 niches**: niche-shared + niche-specific ligand-receptor interactions. **Niche_4 poor**: macrophages + tumor cells colocalization — poor prognosis + immunotherapy resistance. **Niche_11 better**: macrophages + immune cells colocalization — better survival + treatment response. **면역치료 저항성 예측 모델**: Niche_4/11 기반 immunotherapy resistance prediction model 가능성. **핵심**: Pan-cancer 56 LCPs + Niche_4/11 prognosis + immunotherapy resistance prediction — spatial Synthesizing Consolidating. **SCLC Vascular-Immune Crosstalk: 600,000+ Cells · Clinical Translation[11]** Z. Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC의 spatial transcriptomics를 수행한다[11]. **75 patients · 105 specimens · 600,000+ cells · CosMx Spatial Molecular Imager**. **3개 LNM-enriched malignant subclusters**: distinct metabolic + angiogenic programs. **PIHS-1 (pan-immune hotspot 1)**: 독립적 survival predictor. **Vascular-immune crosstalk**: endothelial cells가 cytotoxic T cells와 functional perivascular niches 형성. **면역치료 표적화 시사**: vascular-immune crosstalk 기반 immunotherapy targeting strategy 가능성. **핵심**: SCLC spatial map + PIHS-1 + vascular-immune crosstalk clinical translation outlook — spatial Synthesizing Consolidating. **9월 15일 Validating vs 오늘의 차별점**: 9/15가 **Gao LAR**으로 **spatial characterization**(Validating)을, **Li**으로 **Niche_4/11 prognosis**(Validating)을 제시했다면, 오늘은 **Gao LAR**을 **Group A/B immune activation difference + immunotherapy target prospect**(Synthesizing — 임상 적용 전망)로 재해석하고, **Li**을 **immunotherapy resistance prediction model 시사**(Synthesizing)로, **Zhang**을 **vascular-immune crosstalk 기반 immunotherapy targeting strategy**(Synthesizing — 임상 적용 전망)로 재제시한다. Validating(9/15) → Spatial Synthesizing(9/16). 실무 함의: 암면역 치료 연구팀에서 Gao et al.의 LAR/TLS와 Li et al.의 Niche_4/11 framework를 참조하여 immunotherapy resistance prediction + targeting strategy를 수립해야 한다. *출처: [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-cancer Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang SCLC Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#SpatialTranscriptomics #CancerAtlas #Wang #SPARKLE #BioRxiv #RNALeakage #Correction #Stereo-seq #VisiumHD #Li #CellReportsMedicine #PanCancer #LCP #Niche #Niche4 #Niche11 #Prognosis #ImmunotherapyResistance #Gao #GastricCancer #LAR #TLS #TertiaryLymphoidStructures #PD1 #CD27 #CD8 #DendriticCells #SynthesizingDay #Methodology #Standardization #Integration #Atlas #DailyReport* --- ### Post 8: 오늘의 요약 — Synthesizing(종합) Day 핵심 정리 🧬 **Synthesizing(종합) Day — 9월 16일 핵심 정리** 오늘 Synthesizing Day의 핵심 성과 3가지: **1. Macrocyclic Covalent Peptide + IS110 Dual-Match Logic: Gene Editing/Drug Discovery 新치료 플랫폼 종합** Sawtell et al.(bioRxiv 2026)으로 macrocyclic peptide의 cysteine-to-N-terminal cyclisation으로 covalent peptide inhibitor 발견[1]. Na X.-M. et al.(bioRxiv 2026)으로 IS110 transposon의 sequence-structure dual-match logic으로 target recognition fidelity 확인[2]. Ambardekar et al.(JACC 2026)으로 ACC CRISPR cardiovascular disease statement — hepatocyte targets via LNP, curative treatments imminent[3]. Rui Zhao et al.(Molecular Biomedicine 2026)으로 DNA/RNA editing therapy delivery·genotoxicity·immunogenicity 핵심 병목 종합[4]. CRISPR/drug discovery Synthesizing — **cross-modality therapeutic platform 통합**. **2. AI Preclinical Drug Discovery Multimodal/Digital Twins/Closed-Loop Automation 종합** Cai et al.(Pharmaceuticals 2026)으로 AI preclinical drug discovery 2020-2026 literature review — drug-target·structure·de novo·virtual screening·ADMET 종합 + multimodal AI·digital twins·closed-loop automation今后 방향[5]. Mao et al.(Frontiers Pharmacology 2026)으로 AI Phase I 80-90% 있으나 Phase II ~40% — target validity 미개선 한계 확인[6]. 단백질 AI Synthesizing — **AI preclinical 통합 프레임워크 + 한계 인식**. **3. SPARKLE RNA Leakage Correction + Pan-Cancer Spatial Atlas 통합** Wang S. et al.(bioRxiv 2026)으로 SPARKLE high-resolution spatial transcriptomics RNA leakage 보정[10]. Li et al.(Cell Reports Medicine 2026)으로 12개 암종 56 LCPs + 13 niches + Niche_4/11 prognosis[12]. Gao et al.(Nature Communications 2026)으로 gastric cancer LAR + TLS spatial[16]. Spatial transcriptomics Synthesizing — **methodology 보정 + 통합 atlas framework**. **핵심 인사이트:** Validating(9/15)에서 확인된 FDA 승인里程碑과 검증 데이터들이 오늘 **cross-modality 통합(Sawtell macrocyclic + IS110 + ACC cardiovascular CRISPR), AI- drug delivery 통합(Cai multimodal + Rui Zhao delivery bottlenecks), spatial methodology 보정(SPARKLE + pan-cancer atlas)**으로 Synthesizing하고 있다. *출처: [Sawtell Macrocyclic Covalent Peptide bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.04.749435v1), [Na IS110 Transposon bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.03.19.712850v2), [Ambardekar CRISPR Cardiovascular ACC JACC 2026](https://consensus.app/papers/details/d2b3d0973ec05b0fa332e49d7a7e9a63/), [Rui Zhao DNA RNA Editing Therapy Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Cai AI Preclinical Drug Discovery Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Wang SPARKLE RNA Leakage Correction bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.08.12.744394v2), [Zhang SCLC Spatial Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Li Pan-cancer Spatial Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Gao Gastric Cancer Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Yin AlphaFold Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Mahtha AlphaFold ESMFold Benchmark NAR Genomics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/), [Feldman AlphaFold3 Adversarial Computational 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [DenAdel scFM Dataset Scaling Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Hou Unified scFM Framework bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.01.747412v1), [Sheikh Kresladi Annals Medicine Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Oo FDA Gene Therapy J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)* *#SynthesizingDay #Synthesizing #Summary #Sawtell #Macrocyclic #CovalentPeptide #Cysteine #Na #IS110 #Transposon #DualMatch #Ambardekar #ACC #JACC #Cardiovascular #CRISPR #RuiZhao #DNAEditing #RNAEditing #Cai #Pharmaceuticals #MultimodalAI #DigitalTwin #ClosedLoop #Wang #SPARKLE #RNALeakage #Correction #DenAdel #scFM #DatasetScaling #Plateau #NoScalingLaws #Hou #UnifiedFramework #13FMs #50Datasets #PCA #Li #PanCancer #LCP #Niche #Niche4 #Niche11 #Zhang #SCLC #PIHS1 #Gao #GastricCancer #LAR #TLS #Yin #AlphaFold #ProteinLanguageModels #Mahtha #Benchmark #Feldman #Adversarial #Mao #PhaseII #TargetValidity #Sheikh #Kresladi #Oo #FDA #PlatformTechnology #Shahzad #CGT #Synthesizing #CrossDomain #Integration #DailyReport* --- ## Sources (1차 출처, 10개 이상 URL) [1] [Sawtell et al. — Expanding Macrocyclic Topology through Cysteine-to-N-Terminal Cyclisation Enables Covalent Peptide Inhibitor Discovery. bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.04.749435v1) [2] [Na X.-M. et al. — A sequence-structure dual-match logic enables target recognition fidelity by an IS110 transposon. bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.03.19.712850v2) [3] [Ambardekar et al. — Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement. JACC 2026](https://consensus.app/papers/details/d2b3d0973ec05b0fa332e49d7a7e9a63/) [4] [Rui Zhao et al. — DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects. Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [5] [Cai et al. — From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation. Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/) [6] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/) [7] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/) [8] [Mahtha et al. — Comparative evaluation of the prediction accuracy of AlphaFold and ESMFold for monomeric and dimeric proteins. NAR Genomics and Bioinformatics 2026](https://consensus.app/papers/details/11a60df3938051cc87f7e295ef5e73f2/) [9] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/) [10] [Wang S. et al. — SPARKLE: evidence-constrained correction of local RNA leakage in high-resolution spatial transcriptomics. bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.08.12.744394v2) [11] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/) [12] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [13] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/) [14] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. The Journal of Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [15] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology and Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/) [16] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/) [17] [DenAdel et al. — Evaluating the role of pre-training dataset size and diversity on single-cell foundation model performance. Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/) [18] [Hou et al. — A unified computational framework for benchmarking single-cell foundation models. bioRxiv 2026](https://www.biorxiv.org/content/10.64898/2026.09.01.747412v1)
Research Pulse·2026-09-16
Research Pulse — 2026-09-16
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief